Senicapoc

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Senicapoc
Senicapoc.png
Names
IUPAC name
2,2-bis(4-fluorophenyl)-2-phenylacetamide
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
Properties
C20H15F2NO
Molar mass 323.34 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

Senicapoc (ICA-17043) is a Gardos channel blocker.[1][2]

It has been proposed for use in sickle cell anemia.[3]

The Gardos channel has been identified as KCNN4.[4]

The "ICA" is for Icagen, which is developing the drug.[5]

References[edit]

  1. ^ Ataga KI, Smith WR, De Castro LM, et al. (April 2008). "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood. 111 (8): 3991–7. doi:10.1182/blood-2007-08-110098. PMID 18192510. 
  2. ^ McNaughton-Smith GA, Burns JF, Stocker JW, et al. (February 2008). "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. doi:10.1021/jm070663s. PMID 18232633. 
  3. ^ Ataga KI; Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs. 18 (2): 231–9. doi:10.1517/13543780802708011. PMID 19236269. 
  4. ^ Hoffman JF; Joiner W; Nehrke K; Potapova O; Foye K; Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. doi:10.1073/pnas.1232342100. PMC 165881Freely accessible. PMID 12773623. 
  5. ^ "Icagen - Press Release". Retrieved 2008-12-22.